| |
Monday, October 17, 2022 | 11am ET / 8am PT Given the wide array of post transcriptional and post translational regulatory processes that govern cellular dynamics, additional omics types are needed to capture a more comprehensive understanding of the molecular landscape of a tumor. Register now to learn more.
|
|
Today's Big NewsOct 11, 2022 |
| By Max Bayer Michelle McMurry-Heath is resigning as CEO of BIO days after the Wall Street Journal reported on internal clashes between her and the organization's board. Former BIO board chair and co-founder of GlycoMimetics Rachel King has been named interim CEO. |
|
|
|
By Max Bayer Days after PureTech confirmed speculation of a merger with Nektar, conversations between the two companies have ceased, for now. PureTech says its original statement created the impression that the talks were farther along than they were. |
By Gabrielle Masson Eli Lilly is forecasting that Nimbus Therapeutics will discover new therapies for treating metabolic diseases, partnering up with the biotech and giving it the chance to collect up to $496 million in biobucks. |
By Nick Paul Taylor NMD Pharma has reported phase 1/2a data on its myasthenia gravis candidate, furthering its efforts to treat an aspect of the disease that it thinks therapies from AstraZeneca, argenx, Johnson & Johnson and UCB are unable to address. |
By Nick Paul Taylor One year after its splashy $500 million unveiling, Neumora Therapeutics is back with a series B to keep its multiprogram neuroscience pipeline moving toward and through the clinic. The series B syndicate has put up $112 million, a sum that is big by most standards but dwarfed by the biotech’s first round. |
By Max Bayer BMS-backed Immatics is touting early phase 1 data of its cell therapy program and looking to fundraise off of it, seeking $110 million in a new public offering. It's the most robust data provided by the company to date, although the most promising figures are from just 12 patients. |
By Helen Floersh Researchers have engineered regulatory T cells that home to the pancreas, where they successfully blocked diabetes development in mice. |
By Andrea Park In a case of life imitating orthopedics, Orthofix and SeaSpine—makers of devices to heal bone fractures and bridge gaps in the spine—will fuse together in what they’ve termed a merger of equals. |
By Kevin Dunleavy Researchers at the University of Oxford said their nasal vaccine candidate has come up short in a phase 1 trial, failing to produce a strong immune response in the nasal mucosa of a majority of recipients. The spray also elicited weaker systemic immune responses than intramuscular vaccines. AstraZeneca funded the research. |
By Fraiser Kansteiner The U.S. FDA has logged multiple new quality control lapses at Lilly’s plant in Branchburg, New Jersey, Reuters first reported, citing an agency report seen by the news outlet. Problems at Branchburg stretch back to at least 2020, when the FDA cited Lilly on two counts of inadequate “control of computer systems" there, a Lilly spokesperson said at the time. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about trial results for Eisai and Biogen's Alzheimer’s drug, which were surprisingly good, and we dig into what comes next. We also discuss how Pfizer is ramping up its DTC ad campaign for its COVID shots, most recently spending big on a booster ad for the NFL season. |
|
|---|
|
|
|
Scaling biotechs are at a unique intersection of capital, opportunity and flexibility. And real estate is key to driving business forward. Get answers to six key questions to ensure you have the space and solutions to grow where and when you need to. Learn more.
|
|
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
